Financial Performance - Revenue for the six months ended June 30, 2025, increased to HK$76,587,000, up 4.2% from HK$73,307,000 in 2024[5] - Gross profit rose to HK$20,395,000, representing a 24.5% increase compared to HK$16,382,000 in the previous year[5] - Other income and gains significantly improved to HK$26,133,000 from a loss of HK$10,922,000 in 2024[5] - Loss before tax decreased to HK$30,312,000, down 49.8% from HK$60,342,000 in the same period last year[5] - Loss for the period was HK$29,312,000, a reduction of 49.1% compared to HK$57,579,000 in 2024[6] - Total comprehensive loss for the period was HK$23,016,000, down from HK$69,439,000 in the previous year[6] - Basic and diluted loss per share attributable to ordinary equity holders of the parent was HK(0.48) cents, improved from HK(0.93) cents in 2024[7] Assets and Liabilities - Total non-current assets decreased from HK$1,398,050,000 as of December 31, 2024, to HK$1,342,849,000 as of June 30, 2025, representing a decline of approximately 4.0%[8] - Current assets increased from HK$552,116,000 as of December 31, 2024, to HK$576,273,000 as of June 30, 2025, reflecting an increase of about 4.4%[8] - Net current assets improved from HK$414,105,000 as of December 31, 2024, to HK$448,646,000 as of June 30, 2025, indicating a growth of approximately 8.3%[8] - Total current liabilities decreased from HK$138,011,000 as of December 31, 2024, to HK$127,627,000 as of June 30, 2025, a reduction of about 7.5%[8] - Total non-current liabilities remained relatively stable, with a slight increase from HK$71,729,000 as of December 31, 2024, to HK$71,807,000 as of June 30, 2025[9] - Net assets decreased from HK$1,740,426,000 as of December 31, 2024, to HK$1,719,688,000 as of June 30, 2025, a decline of approximately 1.2%[9] Cash Flow and Investments - Net cash flows generated from operating activities amounted to HK$12,556,000, a significant improvement from a cash outflow of HK$36,938,000 in the same period of 2024[14] - Cash flows from investing activities generated HK$24,865,000, compared to a cash outflow of HK$11,995,000 in 2024, indicating a positive shift in investment performance[15] - The company reported a net increase in cash and cash equivalents of HK$38,161,000, contrasting with a decrease of HK$51,711,000 in the previous year[17] - Cash and cash equivalents at the end of the period stood at HK$117,168,000, up from HK$100,998,000 in 2024[17] Revenue Sources - For the six months ended June 30, 2025, the Group's revenue from contracts with customers was approximately HK$76,587,000, an increase of 4% from HK$73,307,000 for the same period in 2024[31] - Revenue from the sale of goods was HK$69,608,000, up from HK$68,078,000, while revenue from rendering services increased to HK$6,979,000 from HK$5,229,000[32] - 100% of the Group's revenue during the period was generated from customers in Mainland China, with over 92% of non-current assets located in the same region[27] Geriatric Care Business - As of June 30, 2025, the Group operated six geriatric care institutions with a total of 1,243 beds, including 955 beds for medical care services, achieving an average occupancy rate of over 70%[177] - Revenue from geriatric care institutions reached RMB 26.42 million in the first half of 2025, representing a year-on-year increase of 22% compared to RMB 21.64 million in the first half of 2024[177] - The average occupancy rate of the Group's geriatric care institutions was 73% in the first half of 2025, compared to 56% in the first half of 2024[180] - The Group's nursing institutions maintained full occupancy throughout the year, indicating strong recognition from customers and government[176] Share Options and Capital - The company has a share capital of HK$1,211,754,000 as of June 30, 2025, unchanged from December 31, 2024[100] - The 2013 share option scheme has expired as of May 23, 2023, with 146,500,000 share options lapsed and HK$51,934,000 transferred to accumulated losses during the period[101] - The total number of share options granted to directors and substantial shareholders amounts to 60,000,000, with 20,000,000 lapsing during the period[112] - The total number of share options exercised during the period was zero, indicating a potential lack of liquidity or market confidence[111] Financial Assets and Liabilities - The fair value of financial assets measured at fair value as of June 30, 2025, totals HK$165,886,000, with HK$47,209,000 classified as Level 1 and HK$113,675,000 as Level 2[140] - The Group's total financial assets at fair value through profit or loss amount to HK$141,641,000 as of June 30, 2025[140] - The total fair value of financial assets at fair value through profit or loss included HK$118,441,000 in bank wealth management products classified as Level 2[144] Management and Governance - Compensation for key management personnel for the six months ended June 30, 2025, totaled HK$4,513,000, an increase from HK$2,267,000 in the same period of 2024[130] - Performance-related bonuses for key management personnel for the six months ended June 30, 2025, were HK$2,100,000, compared to none in the same period of 2024[130] Contingent Liabilities and Commitments - As of June 30, 2025, the Group had no significant contingent liabilities[123] - The Group's capital commitments as of June 30, 2025, include contracted but not provided for amounts of HK$15,156,000, down from HK$75,822,000 as of December 31, 2024[127]
北京健康(02389) - 2025 - 中期财报